

# Otto S Hoekstra

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7548025/publications.pdf>

Version: 2024-02-01

148  
papers

10,977  
citations

87888

38  
h-index

32842

100  
g-index

154  
all docs

154  
docs citations

154  
times ranked

14345  
citing authors

#	ARTICLE	IF	CITATIONS
1	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 328-354.	6.4	2,188
2	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	10.7	1,612
3	Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3048-3058.	1.6	1,269
4	RECIST 1.1 Update and clarification: From the RECIST committee. <i>European Journal of Cancer</i> , 2016, 62, 132-137.	2.8	1,143
5	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 2320-2333.	6.4	343
6	Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. <i>Nature Communications</i> , 2018, 9, 4664.	12.8	331
7	Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation. <i>Molecular Imaging and Biology</i> , 2016, 18, 788-795.	2.6	214
8	RECIST 1.1 Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. <i>European Journal of Cancer</i> , 2016, 62, 138-145.	2.8	211
9	Sentinel Node Biopsy in Melanoma Patients: Dynamic Lymphoscintigraphy Followed by Intraoperative Gamma Probe and Vital Dye Guidance. <i>World Journal of Surgery</i> , 1997, 21, 788-793.	1.6	141
10	<sup>89</sup> Zr-cetuximab PET imaging in patients with advanced colorectal cancer. <i>Oncotarget</i> , 2015, 6, 30384-30393.	1.8	106
11	Monitoring Response to Antiangiogenic Therapy in Non-Small Cell Lung Cancer Using Imaging Markers Derived from PET and Dynamic Contrast-Enhanced MRI. <i>Journal of Nuclear Medicine</i> , 2011, 52, 48-55.	5.0	98
12	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. <i>Lancet Oncology</i> , The, 2018, 19, e534-e545.	10.7	98
13	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: A prospective multicenter trial. <i>Radiotherapy and Oncology</i> , 2008, 87, 221-229.	0.6	97
14	Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 340-349.	6.4	84
15	Detection of locoregional recurrent head and neck cancer after (chemo)radiotherapy using modern imaging. <i>Oral Oncology</i> , 2009, 45, 386-393.	1.5	83
16	Repeatability of Metabolically Active Tumor Volume Measurements with FDG PET/CT in Advanced Gastrointestinal Malignancies: A Multicenter Study. <i>Radiology</i> , 2014, 273, 539-548.	7.3	82
17	Sentinel lymph node biopsy in clinically N0 T1-T2 staged oral cancer: The Dutch multicenter trial. <i>Oral Oncology</i> , 2014, 50, 1020-1024.	1.5	75
18	ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment. <i>Clinical Cancer Research</i> , 2016, 22, 1642-1652.	7.0	74

#	ARTICLE	IF	CITATIONS
19	First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. <i>Annals of Oncology</i> , 2011, 22, 559-566.	1.2	70
20	Molecular Drug Imaging: <sup>89</sup> Zr-Bevacizumab PET in Children with Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 711-716.	5.0	69
21	Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1829-1839.	2.0	67
22	<sup>18</sup> F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 932-942.	6.4	62
23	Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. <i>Neuro-Oncology</i> , 2020, 22, 412-422.	1.2	59
24	Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 65-79.	6.4	55
25	Early lesion detection with <sup>18</sup> F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1911-1918.	6.4	55
26	Primary staging and follow-up of high risk melanoma patients with whole-body <sup>18</sup> F-fluorodeoxyglucose positron emission tomography. , 1999, 85, 1199-1200.		54
27	Quantification of PD-L1 Expression with <sup>18</sup> F-BMS-986192 PET/CT in Patients with Advanced-Stage Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1455-1460.	5.0	54
28	Repeatability of Quantitative Whole-Body <sup>18</sup> F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1343-1349.	5.0	53
29	Lesion detection by [ <sup>89</sup> Zr]Zr-DFO-girentuximab and [ <sup>18</sup> F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1931-1939.	6.4	53
30	Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium. <i>Journal of Nuclear Medicine</i> , 2021, 62, 332-337.	5.0	53
31	Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index. <i>Journal of Clinical Oncology</i> , 2022, 40, 2352-2360.	1.6	53
32	Performance of <sup>89</sup> Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>PLoS ONE</i> , 2017, 12, e0169828.	2.5	50
33	Radiomics analysis of pre-treatment [ <sup>18</sup> F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2307-2317.	6.4	50
34	Immuno-PET Imaging to Assess Target Engagement: Experience from <sup>89</sup> Zr-Anti-HER3 mAb (GSK2849330) in Patients with Solid Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 902-909.	5.0	50
35	Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). <i>Journal of Clinical Oncology</i> , 2020, 38, 3377-3387.	1.6	46
36	Reproducibility of Tumor Perfusion Measurements Using <sup>15</sup> O-Labeled Water and PET. <i>Journal of Nuclear Medicine</i> , 2008, 49, 1763-1768.	5.0	44

#	ARTICLE	IF	CITATIONS
37	Detecting recurrent laryngeal carcinoma after radiotherapy: room for improvement. <i>European Archives of Oto-Rhino-Laryngology</i> , 2004, 261, 417-22.	1.6	43
38	Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review. <i>Oral Oncology</i> , 2019, 88, 75-83.	1.5	43
39	First in man study of [18F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 1047.	3.3	43
40	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1884-1891.	2.4	42
41	Systematic review: Accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. <i>Head and Neck</i> , 2008, 30, 889-897.	2.0	41
42	Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients. <i>Blood Advances</i> , 2021, 5, 2375-2384.	5.2	40
43	Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. <i>Arthritis Research and Therapy</i> , 2015, 17, 266.	3.5	39
44	124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET). <i>Journal of Nuclear Medicine</i> , 2016, 57, 701-707.	5.0	39
45	<sup>89</sup> Zr-Immuno-PET: Toward a Noninvasive Clinical Tool to Measure Target Engagement of Therapeutic Antibodies In Vivo. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1825-1832.	5.0	38
46	Predictive value of quantitative diffusion-weighted imaging and 18-F-FDG-PET in head and neck squamous cell carcinoma treated by (chemo)radiotherapy. <i>European Journal of Radiology</i> , 2019, 113, 39-50.	2.6	38
47	Quantitative implications of the updated EARL 2019 PET-CT performance standards. <i>EJNMMI Physics</i> , 2019, 6, 28.	2.7	37
48	How to perform a comprehensive search for FDG-PET literature. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 91-97.	2.1	36
49	Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e773-e782.	1.9	33
50	Quantification of <sup>18</sup> F-Fluorocholine Kinetics in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 365-371.	5.0	32
51	Does PET Reconstruction Method Affect Deauville Scoring in Lymphoma Patients?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1167-1169.	5.0	32
52	Optimizing Workflows for Fast and Reliable Metabolic Tumor Volume Measurements in Diffuse Large B Cell Lymphoma. <i>Molecular Imaging and Biology</i> , 2020, 22, 1102-1110.	2.6	32
53	Response evaluation after chemoradiotherapy for advanced nodal disease in head and neck cancer using diffusion-weighted MRI and 18F-FDG-PET-CT. <i>Oral Oncology</i> , 2015, 51, 541-547.	1.5	31
54	Diagnostic value of diffusion-weighted imaging and 18F-FDG-PET/CT for the detection of unknown primary head and neck cancer in patients presenting with cervical metastasis. <i>European Journal of Radiology</i> , 2018, 107, 20-25.	2.6	31

#	ARTICLE	IF	CITATIONS
55	The added value of SPECT-CT for the identification of sentinel lymph nodes in early stage oral cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 998-1004.	6.4	29
56	Feasibility of intraoperative detection of sentinel lymph nodes with 89-zirconium-labelled nanocolloidal albumin PET-CT and a handheld high-energy gamma probe. <i>EJNMMI Research</i> , 2018, 8, 15.	2.5	29
57	Pretreatment screening on distant metastases and head and neck cancer patients: Validation of risk factors and influence on survival. <i>Oral Oncology</i> , 2015, 51, 267-271.	1.5	26
58	Quantitative Comparison of <sup>124</sup> I PET/CT and <sup>131</sup> I SPECT/CT Detectability. <i>Journal of Nuclear Medicine</i> , 2016, 57, 103-108.	5.0	26
59	Epidermal growth factor receptor (EGFR) and prostaglandin-endoperoxide synthase 2 (PTGS2) are prognostic biomarkers for patients with resected colorectal cancer liver metastases. <i>British Journal of Cancer</i> , 2014, 111, 749-755.	6.4	25
60	<sup>18</sup> F-FDG or <sup>3</sup> Deoxy- <sup>18</sup> F-Fluorothymidine to Detect Transformation of Follicular Lymphoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 216-221.	5.0	24
61	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 612-615.	5.0	24
62	Diffusion-weighted EPI- and HASTE-MRI and 18F-FDG-PET-CT early during chemoradiotherapy in advanced head and neck cancer. <i>Quantitative Imaging in Medicine and Surgery</i> , 2014, 4, 239-50.	2.0	24
63	Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC. <i>Lung Cancer</i> , 2014, 85, 205-212.	2.0	23
64	Interaction of quantitative <sup>18</sup> F-FDG PET/CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 529-535.	2.0	23
65	Interobserver Agreement of Interim and End-of-Treatment <sup>18</sup> F-FDG PET/CT in Diffuse Large B-Cell Lymphoma: Impact on Clinical Practice and Trials. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1831-1836.	5.0	23
66	Healthy Tissue Uptake of <sup>68</sup> Ga-Prostate-Specific Membrane Antigen, <sup>18</sup> F-DCFPyL, <sup>18</sup> F-Fluoromethylcholine, and <sup>18</sup> F-Dihydrotestosterone. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1111-1117.	5.0	23
67	Quantitative and Simplified Analysis of <sup>11</sup> C-Erlotinib Studies. <i>Journal of Nuclear Medicine</i> , 2016, 57, 861-866.	5.0	22
68	Repeatability of Quantitative <sup>18</sup> F-Fluoromethylcholine PET/CT Studies in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 721-727.	5.0	22
69	Repeatability of Quantitative <sup>18</sup> F-DCFPyL PET/CT Measurements in Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1320-1325.	5.0	22
70	Improved detection of recurrent laryngeal tumor after radiotherapy using 18FDG-PET as initial method. <i>Radiotherapy and Oncology</i> , 2008, 87, 217-220.	0.6	21
71	A randomized trial of PET scanning to improve diagnostic yield of direct laryngoscopy in patients with suspicion of recurrent laryngeal carcinoma after radiotherapy. <i>Contemporary Clinical Trials</i> , 2007, 28, 705-712.	1.8	20
72	Effectiveness of an 18F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016, 118, 251-256.	0.6	20

#	ARTICLE	IF	CITATIONS
73	[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 8-16.	6.4	20
74	The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup> F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1424-1430.	5.0	20
75	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). <i>Neurosurgery</i> , 2016, 79, 535-540.	1.1	19
76	Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1545-1552.	5.0	19
77	Spatial concordance of DNA methylation classification in diffuse glioma. <i>Neuro-Oncology</i> , 2021, 23, 2054-2065.	1.2	19
78	Assessment of Simplified Methods to Measure <sup>18</sup> F-FLT Uptake Changes in EGFR-Mutated Non-Small Cell Lung Cancer Patients Undergoing EGFR Tyrosine Kinase Inhibitor Treatment. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1417-1423.	5.0	17
79	A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9. <i>Oncotarget</i> , 2016, 7, 2123-2134.	1.8	17
80	Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. <i>PLoS ONE</i> , 2019, 14, e0222844.	2.5	17
81	Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab or no maintenance in patients with diffuse large B-cell lymphoma: Results from a HOVON-Nordic Lymphoma Group study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7504-7504.	1.6	17
82	Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: A feasibility study. <i>European Journal of Radiology</i> , 2014, 83, 1144-1151.	2.6	16
83	Screening for distant metastases in head and neck cancer patients using FDG-PET and chest CT: validation of an algorithm. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 2643-2650.	1.6	16
84	Perioperative PET/CT lymphoscintigraphy and fluorescent real-time imaging for sentinel lymph node mapping in early staged colon cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1495-1505.	6.4	16
85	Variability and Repeatability of Quantitative Uptake Metrics in <sup>18</sup> F-FDG PET/CT of Non-Small Cell Lung Cancer: Impact of Segmentation Method, Uptake Interval, and Reconstruction Protocol. <i>Journal of Nuclear Medicine</i> , 2019, 60, 600-607.	5.0	16
86	Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 389-395.	5.0	16
87	Repeatability of two semi-automatic artificial intelligence approaches for tumor segmentation in PET. <i>EJNMMI Research</i> , 2021, 11, 4.	2.5	15
88	Additional non-sentinel lymph node metastases in early oral cancer patients with positive sentinel lymph nodes. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 961-968.	1.6	14
89	Quantification of O-(2-[18F]fluoroethyl)-L-tyrosine kinetics in glioma. <i>EJNMMI Research</i> , 2018, 8, 72.	2.5	14
90	Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with <sup>18</sup> F-Fluoroazomycin Arabinoside and <sup>15</sup> O-H <sub>2</sub> O PET. <i>Journal of Nuclear Medicine</i> , 2016, 57, 530-535.	5.0	13

#	ARTICLE	IF	CITATIONS
91	Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images. <i>Molecular Imaging and Biology</i> , 2018, 20, 1025-1034.	2.6	13
92	PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11001-11001.	1.6	13
93	Parametric Methods for Quantification of 18F-FAZA Kinetics in Nonâ€“Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1772-1777.	5.0	12
94	Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics. <i>EJNMMI Research</i> , 2019, 9, 12.	2.5	12
95	Quality assessment of positron emission tomography scans: recommendations for future multicentre trials. <i>Acta OncolÃ³gica</i> , 2017, 56, 1459-1464.	1.8	11
96	Repeatability of quantitative 18F-FLT uptake measurements in solid tumors: an individual patient data multi-center meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 951-961.	6.4	11
97	Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody. <i>EJNMMI Research</i> , 2018, 8, 6.	2.5	11
98	Interobserver reproducibility of tumor uptake quantification with 89Zr-immuno-PET: a multicenter analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1840-1849.	6.4	11
99	A Clinical and Experimental Comparison of Time of Flight PET/MRI and PET/CT Systems. <i>Molecular Imaging and Biology</i> , 2015, 17, 714-725.	2.6	10
100	Sensitivity of 18F-fluorodihydrotestosterone PET-CT to count statistics and reconstruction protocol in metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2019, 9, 70.	2.5	10
101	Assessment of Simplified Methods for Quantification of 18F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1221-1227.	5.0	10
102	Lesion Detection and Interobserver Agreement with Advanced Image Reconstruction for <sup>18</sup> F-DCFPyL PET/CT in Patients with Biochemically Recurrent Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 210-216.	5.0	10
103	Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1075-1082.	6.4	10
104	Diagnostic Performance of [18F]FDG PET in Staging Grade 1â€“2, Estrogen Receptor Positive Breast Cancer. <i>Diagnostics</i> , 2021, 11, 1954.	2.6	10
105	Response evaluation after chemoradiotherapy for advanced staged oropharyngeal squamous cell carcinoma: a nationwide survey in the Netherlands. <i>European Archives of Oto-Rhino-Laryngology</i> , 2015, 272, 3507-3513.	1.6	9
106	Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237). <i>Nuclear Medicine and Biology</i> , 2016, 43, 63-72.	0.6	9
107	Cost-effectiveness of response evaluation after chemoradiation in patients with advanced oropharyngeal cancer using 18Fâ€“FDG-PET-CT and/or diffusion-weighted MRI. <i>BMC Cancer</i> , 2017, 17, 256.	2.6	9
108	Use of Diffusion-Weighted Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Combined With Computed Tomography in the Response Assessment for (Chemo)radiotherapy in Head and Neck Squamous Cell Carcinoma. <i>Clinical Oncology</i> , 2018, 30, 780-792.	1.4	9

#	ARTICLE	IF	CITATIONS
109	Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. <i>EJNMMI Research</i> , 2019, 9, 57.	2.5	8
110	Quantitative parametric maps of O-(2-[ <sup>18</sup> F]fluoroethyl)-L-tyrosine kinetics in diffuse glioma. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 895-903.	4.3	8
111	Interobserver Agreement on Automated Metabolic Tumor Volume Measurements of Deauville Score 4 and 5 Lesions at Interim <sup>18</sup> F-FDG PET in Diffuse Large B-Cell Lymphoma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1531-1536.	5.0	8
112	Letter to the Editor re: Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. <i>Molecular Imaging and Biology</i> , 2020, 22, 15-17.	2.6	7
113	Imaging Responses to Immunotherapy with Novel PET Tracers. <i>Journal of Nuclear Medicine</i> , 2020, 61, 641-642.	5.0	7
114	Updating PET/CT performance standards and PET/CT interpretation criteria should go hand in hand. <i>EJNMMI Research</i> , 2019, 9, 95.	2.5	7
115	Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2534-2534.	1.6	7
116	Calibration of PET/CT scanners for multicenter studies on differentiated thyroid cancer with 124I. <i>EJNMMI Research</i> , 2016, 6, 39.	2.5	6
117	The adverse impact of surveillance intervals on the sensitivity of FDG-PET/CT for the detection of distant metastases in head and neck cancer patients. <i>European Archives of Oto-Rhino-Laryngology</i> , 2017, 274, 1113-1120.	1.6	6
118	Is <sup>11</sup> C-Methionine PET an alternative to <sup>18</sup> F-FDG PET for identifying recurrent laryngeal cancer after radiotherapy?. <i>Clinical Otolaryngology</i> , 2019, 44, 124-130.	1.2	6
119	Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example. <i>EJNMMI Research</i> , 2021, 11, 74.	2.5	6
120	Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239414.	2.5	6
121	Pretreatment screening for distant metastases in the Dutch head and neck centers: 10 years later. <i>European Archives of Oto-Rhino-Laryngology</i> , 2016, 273, 3287-3291.	1.6	5
122	Detection of residual head and neck squamous cell carcinoma after (chemo)radiotherapy: a pilot study assessing the value of diffusion-weighted magnetic resonance imaging as an adjunct to PET-CT using 18 F-FDG. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2017, 124, 296-305.e2.	0.4	4
123	Parametric Method Performance for Dynamic <sup>3</sup> -Deoxy- <sup>3</sup> -18F-Fluorothymidine PET/CT in Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Carcinoma Patients Before and During Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 920-925.	5.0	4
124	Baseline and longitudinal variability of normal tissue uptake values of [ 18 F]-fluorothymidine-PET images. <i>Nuclear Medicine and Biology</i> , 2017, 51, 18-24.	0.6	4
125	Validation of [18F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor. <i>EJNMMI Research</i> , 2018, 8, 22.	2.5	4
126	Aberrant patterns of PET response during treatment for DLBCL patients with MYC gene rearrangements. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, , 1.	6.4	4



#	ARTICLE	IF	CITATIONS
127	Early 18F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2016, 11, e0155178.	2.5	4
128	18FDG SUV in the primary tumor and lymph node metastases is not predictive for development of distant metastases in high risk head and neck cancer patients. Oral Oncology, 2015, 51, 536-540.	1.5	3
129	<sup>89</sup> Zr-rituximab PET/CT to detect neurolymphomatosis. American Journal of Hematology, 2016, 91, 649-650.	4.1	3
130	Evaluation of neck node response after radiotherapy: minimizing equivocal results. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 605-608.	6.4	3
131	Performance Evaluation of a Semi-automated Method for [18F]FDG Uptake in Abdominal Visceral Adipose Tissue. Molecular Imaging and Biology, 2019, 21, 159-167.	2.6	3
132	Evaluation of Cost-effectiveness of FDG-PET in Non-Small Cell Lung Cancer. PET Clinics, 2006, 1, 329-337.	3.0	2
133	Quantitative Issues in Response Measurement by PET. PET Clinics, 2008, 3, 5-11.	3.0	2
134	Effects of Reusing Baseline Volumes of Interest by Applying (Non-)Rigid Image Registration on Positron Emission Tomography Response Assessments. PLoS ONE, 2014, 9, e87167.	2.5	2
135	ImmunoPET imaging with 89Zr-cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 11102-11102.	1.6	2
136	Androgen receptor and estrogen receptor imaging in patients with metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 11553-11553.	1.6	2
137	ECLYPS: Multicenter trial of FDG-PET/CT to detect residual nodal disease in locally advanced head-and-neck squamous cell carcinoma (LAHNSCC) after chemoradiotherapy (CRT).. Journal of Clinical Oncology, 2016, 34, 6021-6021.	1.6	2
138	Pharmacokinetics of cetuximab and tumor uptake of <sup>89</sup> Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer.. Journal of Clinical Oncology, 2017, 35, e15117-e15117.	1.6	2
139	18f-FDG PET/CT Baseline Radiomics Features Improve the Prediction of Treatment Outcome in Diffuse Large B-Cell Lymphoma Patients. Blood, 2020, 136, 27-28.	1.4	1
140	A randomized, phase II study of repeated rhenium-188-HEDP (rhenium) combined with docetaxel versus docetaxel alone in castration resistant prostate cancer (CRPC) metastatic to bone: The Taxium II trial.. Journal of Clinical Oncology, 2016, 34, 5081-5081.	1.6	1
141	3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body 18F-Fluorodeoxyglucose and 89Zr-Rituximab PET Scans. Diagnostics, 2022, 12, 596.	2.6	1
142	SAT0531...Association between Presence of Subclinical Synovitis on (R)-11C-PK11195 Positron Emission Tomography and Clinical Outcome in Rheumatoid Arthritis Patients without Clinical Synovitis. Annals of the Rheumatic Diseases, 2013, 72, A761.2-A761.	0.9	0
143	Reply: Should we assess repeatability of PET quantitative uptake measurements of each 18F-labelled tracer?. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1274-1275.	6.4	0
144	11C-sorafenib and 15O-H2O PET for early evaluation of sorafenib therapy. Journal of Nuclear Medicine, 2020, 62, jnumed.120.251611.	5.0	0

#	ARTICLE	IF	CITATIONS
145	Does 18F-Fluorodeoxyglucose Outperform 18F-Fluorothymidine When Using Positron Emission Tomography in Predicting Transformation of Indolent Non-Hodgkin's Lymphoma,. Blood, 2011, 118, 3658-3658.	1.4	0
146	Towards qualification of FDG PET as biomarker of response to neo-adjuvant therapy: A meta-analysis.. Journal of Clinical Oncology, 2013, 31, e22128-e22128.	1.6	0
147	PERCISTence: Strength or Stubbornness? (perspective on "From RECIST to PERCIST: Evolving) Tj ETQq1 1 0.784314 rgBT /Overloc Journal of Nuclear Medicine, 2020, 61, 199S-226S.	5.0	0
148	Cost-effectiveness of shortening treatment duration based on interim PET outcome in patients with diffuse large B-cell lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.4	0